Encouraging results of brain death study redefine Death Declaration parameters
Biotechnology company Revita Life Sciences, had indicated in 2016 about its intent about its advanced research, into the clinical intervention in the condition of brain death in humans.
Experts are working toward reversing brain death patients to redefine the 52-year-old brain dead declaration criteria. Irreversibility is closely related to technological advances, and we have no doubt that brain lesions which are irreversible nowadays might be reparable.

We have arrived to a technological point with convergence of the tools of regenerative biotechnology, resuscitation/reanimation research, and clinical neuroscience it is now possible what was considered an end point before.
Biotechnology company Revita Life Sciences (https://revitalife.co.in), had indicated in 2016 about its intent about its advanced research, into the clinical intervention in the condition of brain death in humans.
Results of the first phase are encouraging, soon we may have a special medical fraternity to relook into this matter, experts say we can save more than ten lakh people every year with the help of Regenerative therapeutic applications and brain stimulation techniques.
Revita Life Sciences focuses on translational regenerative therapeutic applications. “We have proactively continued to advance our multi-modality protocol, as an extended treatment before extubation in an attempt to reverse the state of brain death” said Pranjal Agrawal, CEO Revita Life Sciences.
“This treatment approach has yielded some very encouraging initial outcome signs, ranging from minor observations on blood pressure changes with response to painful stimuli, to eye-opening and finger movements, with the corresponding transient to permanent reversal changes in EEG patterns,” he added further.
Meanwhile the first exploratory study of the company titled, “Non-randomized, open-labelled, interventional, Single Group, and Proof of Concept Study with Multi-modality Approach in Cases of Brain Death due to Traumatic Brain Injury Having Diffuse Axonal Injury”, is ongoing.
It has shown quite enthusiastic early results, which may change the concept of brain death and probably even the concept of irreversible cell death.
The intervention primarily involves the Intrathecal administration of umbilical cord stem cells daily along with Transcranial laser & magnetic stimulation.
Dr.Himanshu Bansal, Chief Scientific officer with Revita Life Sciences and Director of Mother cell said “We are in the process of publishing our initial retrospective results, as well as ongoing early results, in a peer-reviewed journal. These initial findings will prove invaluable to the future evolution of the programme, as well as in progressing the development multi-modality regenerative therapeutics for the full range of the severe disorders of consciousness, including coma, PVS, the minimally conscious state, and a range of other degenerative CNS conditions in humans.”
A lot of advancement has happened in medical science in last 52 years, especially in cell therapy, which was previously considered to be irretrievable. Now revival or rejuvenation is possible, therefore many scientists believe that the definition of brain death needs to be revised.
While the long term goal is to find a solution for “infusing life”, the short term purpose of these types of studies is not as dramatic, says the company.
There are many anecdotal reports of brain death reversal across the world. This study is to establish this very fact in a scientific and controlled manner. It will also give a fair chance to young individuals who are declared brain dead, especially after trauma.
What is Brain Death?
Death is defined as the termination of all biological functions that sustain a living organism.
While brain death is described as the complete and irreversible loss of brain function (including involuntary activity necessary to sustain life), as defined in the 1968 report of the Ad Hoc Committee of the Harvard Medical School. Either directly through trauma, or indirectly through secondary disease indications, brain death is the final pathological state that over 60 million people globally transfer through each year.
About Revita Life Sciences
Revita Life Sciences is a biotechnology company focused on the development of stem cell therapies and regenerative medicine interventions that target areas of significant unmet medical need. Revita is led by Dr. Himanshu Bansal MS ,who has spent over two decades developing novel MRI based classifications of spinal cord injuries, as well as comprehensive treatment protocols with autologous tissues including bone marrow stem cells, dural nerve grafts, nasal olfactory tissues, and omental transposition.
Disclaimer: This is a company press release. No HT journalist was involved in the creation of this content.

E-Paper

